What is the difference between adjuvant and neoadjuvant treatment for Liver Cancer

Adjuvant vs. Neoadjuvant Treatment for Liver Cancer

Great question—understanding the timing and purpose of these treatments is important for your care planning. Let me break down the key differences:

NEOADJUVANT THERAPY (Treatment Before Surgery)

Neoadjuvant therapy is treatment given before your main surgical procedure. For liver cancer patients, this approach aims to:

• Shrink the tumor before surgery to make it easier to remove completely
• Improve surgical outcomes by reducing tumor burden
• Assess how your cancer responds to treatment before committing to surgery

According to NCCN Guidelines for Hepatocellular Carcinoma, neoadjuvant approaches are being studied with immunotherapy drugs. For example, a clinical trial using cemiplimab (an immunotherapy) before surgery found that 20 of 21 patients were able to successfully undergo resection (surgical removal). Another trial tested nivolumab (with or without ipilimumab) before surgery, with about one-third of patients showing major pathologic response (significant tumor shrinkage).

ADJUVANT THERAPY (Treatment After Surgery)

Adjuvant therapy is treatment given after your surgery is complete. Its purpose is to:

• Reduce the risk of cancer recurrence (the cancer coming back)
• Eliminate any remaining microscopic cancer cells that surgery may have missed
• Improve long-term survival outcomes

According to NCCN Guidelines, adjuvant therapy options for liver cancer patients include:

• Hepatic arterial infusion chemotherapy (HAIC) with FOLFOX - A clinical trial showed this significantly improved disease-free survival (20.3 months vs. 10.0 months without treatment) in patients with microvascular invasion (MVI—cancer cells found in blood vessels)
• Transarterial chemoembolization (TACE) - Studies show this can improve overall survival, especially in certain patient groups
• Sorafenib - An antiangiogenic drug (blocks blood vessel formation) tested in the STORM trial, though results were mixed

Key Differences at a Glance

| Aspect | Neoadjuvant | Adjuvant | |--------|-------------|----------| | When | Before surgery | After surgery | | Goal | Shrink tumor; improve surgery | Prevent recurrence; improve survival | | Timing | Weeks/months before operation | Begins after recovery from surgery | | Decision | Made before knowing surgical findings | Made based on final pathology results |

Which Approach for Your Situation?

Your oncologist will determine which approach (or combination) is appropriate based on:

• Your tumor size and stage
• Whether your cancer has spread to blood vessels (microvascular invasion)
• Your liver function and overall health
• Whether you're a candidate for surgery

Questions to ask your healthcare team:

1. Based on my specific tumor characteristics, do you recommend neoadjuvant therapy before surgery, adjuvant therapy after surgery, or both?
2. What are the expected benefits and side effects of the specific treatment you're recommending?
3. How will we measure whether the treatment is working? (imaging scans, tumor markers, etc.)
4. If I receive neoadjuvant therapy, how will you decide if surgery is still the best next step?
5. Are there clinical trials available that might be appropriate for my situation?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.